



PPD

929 North Front Street
Wilmington, NC 28401-3331

Telephone: +910 251 0081

Facsimile: +910 762 5820

E-mail: info@ppdi.com

Website: www.ppdi.com

With offices in 30 countries, PPD has more than 10,000 professionals worldwide.

Principal Officers:

Fred N. Eshelman,
Vice Chairman and CEO

William Sharbaugh,
Chief Operating Officer

Daniel Darazsdi, *Chief Financial Officer*

Judd Hartman,
General Counsel and Secretary

Paul Covington,
Executive Vice President, Development

William Richardson,
Senior Vice President, Global Business Development

Areas of Expertise:

- Preclinical/Phase I
- Phase II-IIIb
- Post-Approval
- Labs

PPD

CORPORATE PROFILE:

World-class teams...strong therapeutic expertise...high-quality services...leading-edge technologies...global infrastructure and leadership—these qualities are why PPD is at the forefront of the drug development services market.

Founded in 1985 as a one-person consulting firm by Dr. Fred Eshelman, today PPD is a \$1.2 billion, 10,000-employee global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. With offices in more than 30 countries, our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. Our innovative technologies, therapeutic expertise and commitment to quality are why most of the top 50 pharmaceutical and biotechnology companies rely on us. Our focus is to help clients maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients.

Over the past year, PPD has experienced a strong demand for its development services, driven by pharmaceutical, biotechnology and government-sponsored research and development. One key highlight for 2007 is our compound partnering program. Our strategy provides a seamless connection between our development resources and the discovery efforts of our partners. By leveraging our core competencies and extensive experience in drug development, our compound partnering approach enables us to rapidly

and flexibly adapt drug development resources and speed the decision-making cycle in key programs to save our partners time and money in their drug development programs. We currently have five compounds in various stages of development and continue to seek additional compounds to in-license/partner.

Other key highlights focused on additions to our expertise and global growth and expansion. In 2007, PPD announced new executive leadership positions to guide future growth. We named Bill Sharbaugh as chief operating officer and Dan Darazsdi as chief financial officer.

To support the growing demand for our services, PPD added offices in North America, Scotland, Greece, Australia, Denmark, Peru and Portugal. By expanding our people, systems and infrastructure in locations that meet the needs of our clients, we are well-positioned to service the biopharmaceutical industry as it increasingly relies on global outsourcing to speed drug development and reduce costs.



Dr. Fred Eshelman
Vice Chairman & Chief Executive Officer

"With a focus on consistent quality and execution, exceptional customer service and constant innovation, PPD's goal is to be at the forefront of our rapidly changing industry. Our dedicated global employees take great pride in setting the bar high to capitalize on opportunities that help our clients accelerate delivery of safe and effective medicines to patients."

PRODUCTS AND SERVICES

Discovery Sciences/ Compound Partnering

Applying scientific expertise for drug discovery as well as resources for early compound assessment and development within a proven, innovative compound partnering program

- Biomarker services
- Specialized anticancer preclinical lab services and consulting for preclinical-Phase III

Development Services

Providing comprehensive product development and post-approval services for biopharmaceuticals and devices

- Phase I clinic
- Full service Phase II-IIIb clinical studies for multinational regulatory submissions
- GLP bioanalytical, cGMP product analysis, biomarker and Phase I-IV global central labs
- Therapeutic and specialty groups with

dedicated project teams

- Post-approval services including epidemiology, risk management and outcomes research; late-stage trials; medical information; product safety; registries and observational studies
- Clinical data management and information solutions, including consulting and proprietary software tools to speed collection, analysis and reporting of clinical data